Results 181 to 190 of about 136,011 (340)

Effect of bevacizumab (Avastin TM ) on mitochondrial function of in vitro retinal pigment epithelial, neurosensory retinal and microvascular endothelial cells

Indian Journal of Ophthalmology, 2013
Purpose: To evaluate the effect of bevacizumab on the mitochondrial function of human retinal pigment epithelial (ARPE-19), rat neurosensory retinal (R28) and human microvascular endothelial (HMVEC) cells in culture.
Saurabh Luthra, Ashish Sharma, Joyce Dong, Aneesh Neekhra, Ana L Gramajo, Gail M Seigel, M Cristina Kenney, Baruch D Kuppermann   +7 more
doaj   +1 more source

Transcriptome signature for the identification of bevacizumab responders in ovarian cancer [PDF]

arXiv
The standard of care for ovarian cancer comprises cytoreductive surgery, followed by adjuvant platinum-based chemotherapy plus taxane therapy and maintenance therapy with the antiangiogenic compound bevacizumab and/or a PARP inhibitor. Nevertheless, there is currently no clear clinical indication for the use of bevacizumab, highlighting the urgent need
arxiv  

NEOADJUVANT WEEKLY NAB-PACLITAXEL PLUS CARBOPLATIN FOLLOWED BY DOXORUBICIN PLUS CYCLOPHOSPHAMIDE WITH BEVACIZUMAB ADDED CONCURRENTLY TO CHEMOTHERAPY FOR OPERABLE TRIPLE-NEGATIVE INVASIVE BREAST CANCER [PDF]

, 1969
Jasgit C. Sachdev, Jessica N. Snider, Jeffrey W. Allen, Lee S. Schwartzberg, Robyn R. Young, Ahmed Javed, Matthew Smeltzer, Furhan Yunus, Carmel S. Verrier, Mohammad Jahanzeb   +9 more
openalex   +1 more source

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

Journal of Clinical Oncology, 2015
PURPOSE One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response (pCR) with standard neoadjuvant chemotherapy (NACT).
W. Sikov, D. Berry, C. Perou, Baljit Singh, C. Cirrincione, S. Tolaney, C. Kuzma, T. Pluard, G. Somlo, E. Port, M. Golshan, J. Bellon, Deborah Collyar, O. Hahn, L. Carey, C. Hudis, E. Winer   +16 more
semanticscholar   +1 more source

Molecular subtyping and precision therapy for esophageal cancer

Interdisciplinary Medicine, EarlyView.
The molecular typing of esophageal cancer based on genome, transcriptome, proteome, and multi‐omics revealed various molecular features and provided potential targets for the precision therapy. Recent trials have shown that immunotherapy or molecular targeted therapy plus chemoradiotherapy can improve overall survival and progression‐free survival in ...
Guangkun Pei, Zhuoran Liang, Bianli Gu, Linlin Shi, Ze‐Xian Liu, Shegan Gao   +5 more
wiley   +1 more source

Benchmarking Histopathology Foundation Models for Ovarian Cancer Bevacizumab Treatment Response Prediction from Whole Slide Images [PDF]

arXiv
Bevacizumab is a widely studied targeted therapeutic drug used in conjunction with standard chemotherapy for the treatment of recurrent ovarian cancer. While its administration has shown to increase the progression-free survival (PFS) in patients with advanced stage ovarian cancer, the lack of identifiable biomarkers for predicting patient response has
arxiv  

Utility of circulating tumor DNA in secondary liver malignancies: What we know and what is to come

Journal of Surgical Oncology, EarlyView.
Abstract Secondary liver malignancies are a serious and challenging global health concern. Secondary metastasis to the liver is most commonly from colorectal cancer that has metastatically spread through splanchnic circulation. Metastatic diseases can portend poor prognosis due to the progressive nature typically found on detection.
Chase J. Wehrle, Noah X. Tocci, Keyue Sun, Chunbao Jiao, Hanna Hong, Abby Gross, Erlind Allkushi, Melis Uysal, Maureen Whitsett Linganna, Katheryn Stackhouse, Koji Hashimoto, Andrea Schlegel, R. Matthew Walsh, Charles Miller, David C. H. Kwon, Federico Aucejo   +15 more
wiley   +1 more source

Optimizing First-Line Therapeutics in Non-Small Cell Lung Cancer: Insights from Joint Modeling and Large-Scale Data Analysis [PDF]

arXiv
Non-small cell lung cancer (NSCLC) is often intrinsically resistant to several first- and second-line therapeutics and can rapidly acquire further resistance after a patient begins receiving treatment. Treatment outcomes are therefore significantly impacted by the optimization of therapeutic scheduling.
arxiv  

Bevacizumab in Renal-Cell Cancer [PDF]

, 2003
Guru Sonpavde
openalex   +1 more source

Trends in Immunotherapy (IO) Use and Survival Among Patients With High‐Incidence Stage IV Cancers Across the United States

Journal of Surgical Oncology, EarlyView.
ABSTRACT Background and Objectives IO has transformed cancer management, but its adoption in advanced cancer patients varies by tumor type. With more Stage IV patients undergoing surgery, understanding site‐specific outcomes in these challenging patients is essential.
Samantha C. Warwar, Lauren M. Janczewski, Gladys M. Rodriguez, Jeffrey D. Wayne, David J. Bentrem   +4 more
wiley   +1 more source